Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

• The study is a randomized clinical trial to assess a natural formula of vanillin & wheat germ oil to treat and stop the clinical progression of COVID-19.

• The study aims to treat people with mild-to-moderate COVID-19 before their cases become severe.

• The study duration is a 5-day experimental intervention and an extended 4 weeks follow up.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alexandria University
• Collaborators: Assoc. Prof. Ayman Baeis; Dr. Noha Alaa Eldine Hassan Hamdy; Ph. Hanya Hesham Sweilam

Criteria

Inclusion Criteria:

1. PCR confirmed diagnosis for COVID-19.

2. Age ≥18 years.

3. Both genders

4. The disease started within 7 days (ideally 72 hours) of diagnosis or clinical deterioration.

5. Patients diagnosed as mild or moderate

Exclusion Criteria:

1. Patients diagnosed with severe Illness: Individuals who have SpO2 <92% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%.

2. General: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation, and advanced cardiovascular diseases.

3. Allergy to Vanilla flavor, vanillin, or wheat germ oil

4. Active cancer